A Swedish Biotech Just Landed a $500M Moderna Deal

Moderna and Sweden's Nanexa sign a deal worth up to $500M to develop longer-lasting, more stable injectable mRNA therapies

16 Jun 2026

Moderna has signed a license and option agreement with Swedish biotech Nanexa, putting up to USD 500 million in milestone payments on the line. The deal centers on PharmaShell, Nanexa's coating platform designed to improve how mRNA compounds are released and stabilized in injectable form. Nanexa picks up USD 3 million upfront to get the work started.

The structure is built for expansion. Moderna begins with a license covering one compound, with options to add four more as results emerge. Tiered royalties on future sales are included, giving Nanexa financial skin in the game well beyond the opening check.

David Westberg, CEO of Nanexa, kept his welcome brief. "We are excited to partner with Moderna, a pioneer and leader in the field of mRNA medicines, to explore the potential of our PharmaShell platform and to support the development of improved products for Moderna," he said. His words pointed at a real gap: keeping mRNA potent and releasing it predictably in injectable formats has been one of the field's stubborn problems.

For the wider industry, the deal signals something worth watching. Delivery-enhancement technologies are drawing serious money as drug developers push mRNA beyond vaccines into chronic-disease and preventive-care territory.

Long-acting injectables reduce how often patients need a dose and, by extension, how often they skip one. Nanexa, a European company that was not exactly a household name outside the sector, gains both credibility and capital from one of the field's most recognized players.

Milestone triggers are tied to development and commercialization stages, meaning the financial rewards are paced against real progress rather than front-loaded on promise alone. The agreement points toward a near-term pipeline of more durable mRNA treatments, assuming the clinical data cooperates.